Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: Efficacy and cardiac safety from the GEICAM/2004-05 study

Annals of Oncology

Volumn 22, Issue 12, 2011, Pages 2591-2596

  Martin M ^a   Sanchez Rovira P ^b   Munoz M ^c   Baena Canada J M ^d   Mel, J R ^e   Margeli, M ^f   Ramos, M ^g   Martinez E ^h   Garcia Saenz J A ^a   Casado, A ^a   Jaen A M ^b   Gonzalez Farre X ^c   Escudero, M J ⁱ   Rodriguez Martin, C ⁱ   Carrasco, E ⁱ  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Medical Oncology Department   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^e HOSPITAL XERAL CALDE   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g Centro Oncologico de Galicia   (Spain)

^h HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

ⁱ GEICAM   (Spain)

Author keywords

Anthracycline; Chemotherapy; HER2; Metastatic breast cancer; Pegylated liposomal doxorubicin; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOODSTREAM INFECTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MENSTRUAL IRREGULARITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SKIN EXFOLIATION; STOMATITIS; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80053109887     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr024     Document Type: Article

References (25)

1. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
3. O'Brien M.E., Wigler N., Inbar M. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-449.
4. Vail D.M., Amantea M.A., Colbern G.T. et al. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004; 31(6 Suppl 13): 16-35.
5. Kim E., Gaiotti D.A., Volm M.D. et al. Reversible cardiotoxicity from pegylated liposomal doxorubicin plus trastuzumab: results from 2 prospective studies. Breast Cancer Res Treat 2004; 88: S204: abstr 5058.
6. El-Rayes B.F., Ibrahim D., Shields A.F. et al. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Invest New Drugs 2005; 23: 57-62.
7. Overmoyer B., Silverman P., Holder L.W. et al. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer 2005; 6: 150-157.
8. Trudeau M.E., Clemons M.J., Provencher L. et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 2009; 27: 5906-5910.
9. Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205.
10. Wolff A.C., Hammond M.E.H., Schwartz G.N. et al. American Society of Clinical Oncology-College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
11. Dhesy-Thind B., Pritchard K.I., Messersmith H. et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008; 109: 209-229.
12. Vogel C.L., Cobleigh M.A., Tripathy D. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
13. Gianni L. Never use anthracyclines with trastuzumab: it is time to reconsider the taboo. Breast Cancer Res Treat 2009; 117: 599-601.
14. Chia S., Clemons M., Martin L.A. et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006; 24: 2773-2778.
15. Andreopoulou E., Gaiotti D., Kim E. et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2007; 7: 690-696.
16. nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase Ii trial. Breast Cancer Res Treat 2009; 117: 591-598.
17. Untch M., Muscholl M., Tjulandin S. et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 2010; 28: 1473-1480.
18. Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-384.
19. Inoue K., Nakagami K., Mizutani M. et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 2010; 119: 127-136.
20. Papaldo P., Fabi A., Ferreti G. et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol 2006; 17: 630-636.
21. Jahanzeb M., Mortimer J.E., Yunus F. et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002; 7: 410-417.
22. Romond E.H., Perez E.A., Bryant J. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
23. Perez E., Suman V.J., Davidson N.E. et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastruzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. SABCS 2009; abstr 80.
24. Slamon D, Eierman W, Robert N et al. BCIRG 006 trial: 2nd interim analysis of phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (THC) in HER2-positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium 2006. abstr 52.
25. Rayson D, Suter T, van der Vegt S. et al. BACH: a randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)-cardiac safety analysis (2010 ASCO Ann Meet Proc (Post-Meeting Edition) J Clin Oncol 2010;28 (15 SUPPL): 559.